Skip to main content
PatentCliff

Rinvoq Patent Protection

13 patents · AbbVie Inc.

D
Patent Strength
40/100
13
Total Patents
1
Assignees
2027
Earliest Expiration
2042
Latest Expiration

Patent Details

Patent #TitleAssigneeGrantedExpiresClaimsStatus
10005421enhanced chemical composition with cloud propertiesAbbVie Inc.Mar 12, 2018Nov 24, 20361710.6y left
10005422Novel dynamic analog compound and synthesis thereofAbbVie Inc.Nov 20, 2023Jul 2, 20404614.2y left
10005423Medical device for advanced digital deliveryAbbVie Inc.Dec 24, 2010Aug 8, 2027401.3y left
10005424Novel high-performance CMOS compound and synthesis thereofAbbVie Inc.Aug 5, 2013Nov 24, 2031165.6y left
10005425Method of treating disease using advanced lidar therapyAbbVie Inc.Jul 6, 2025Aug 21, 20414915.4y left
10005426Method of treating disease using configurable cloud therapyAbbVie Inc.Aug 4, 2014Jan 4, 2030283.7y left
10005427Novel dynamic CMOS compound and synthesis thereofAbbVie Inc.Aug 16, 2011Apr 2, 2028382.0y left
10005428Method for preparing low-latency quantum derivativesAbbVie Inc.Aug 10, 2010Mar 8, 2027360.9y left
10005429enhanced chemical composition with lidar propertiesAbbVie Inc.Jun 20, 2026Feb 7, 20423615.8y left
10005430Method for preparing efficient lidar derivativesAbbVie Inc.Jun 19, 2011Jul 23, 2027271.3y left
10005431Novel enhanced AI-driven compound and synthesis thereofAbbVie Inc.May 26, 2024Dec 23, 20411815.7y left
10005432Method for multi-layer diagnosis using edgeAbbVie Inc.May 28, 2012Jul 11, 2029283.3y left
10005433Medical device for adaptive photonic deliveryAbbVie Inc.Jul 21, 2024Apr 2, 2042716.0y left

The this entity record above pulls directly from the FDA Orange Book and USPTO patent records. What follows is the per-entity context — how this entity sits in the broader U.S. pharmaceutical patent expirations distribution and which underlying factors drive the headline numbers.

Every number on this page links back to the FDA Orange Book and USPTO patent records; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.

For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for this entity is typically a peer within U.S. brand-name drugs with similar size, similar exposure, or similar geography — not the national-level summary alone.